Literature DB >> 1938689

Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli.

B Fantin1, S Ebert, J Leggett, B Vogelman, W A Craig.   

Abstract

A murine thigh-infection model was used to determine the effect of certain host- and drug-related factors on the duration of the in-vivo postantibiotic effect (PAE) observed with aminoglycosides against Gram-negative bacilli. The role of neutrophils (PMNs), pharmacokinetics and variation among species and strains were studied. PAEs were quantitated after a single injection of gentamicin or amikacin. PAEs were several hours longer in normal mice than in neutropenic mice, in mice with renal impairment than in those with normal renal function, and with strains of Klebsiella pneumoniae than with strains of Escherichia coli, Serratia marcescens and Enterobacter cloacae. Among the 15 strains of Enterobacteriaceae studied, the duration of the in-vivo PAE did not correlate with MIC, duration of in-vitro PAE, and extent of in-vivo bactericidal activity. We conclude that prolonged PAEs are consistently observed in vivo with aminoglycosides against Enterobacteriaceae, and that this duration is enhanced in the presence of PMNs and by pharmacokinetic properties simulating those observed in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1938689     DOI: 10.1093/jac/27.6.829

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  D Szabó; A Máthé; Z Filetóth; P Anderlik; L Rókusz; F Rozgonyi
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model.

Authors:  Laurent Dubé; Jocelyne Caillon; Christèle Gras-Le Guen; Cédric Jacqueline; Marie-France Kergueris; Jean-Claude Granry; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 3.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.

Authors:  Sara K Olofsson; Patricia Geli; Dan I Andersson; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.

Authors:  M Tod; O Lortholary; D Seytre; R Semaoun; B Uzzan; L Guillevin; P Casassus; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model.

Authors:  D Bugnon; G Potel; Y Q Xiong; J Caillon; M F Kergueris; P Le Conte; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

7.  Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis.

Authors:  I B Xue; P G Davey; G Phillips
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 8.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

9.  A data-based mathematical modelling study to quantify the effects of ciprofloxacin and ampicillin on the within-host dynamics of Salmonella enterica during treatment and relapse.

Authors:  Myrto Vlazaki; Omar Rossi; David J Price; Callum McLean; Andrew J Grant; Pietro Mastroeni; Olivier Restif
Journal:  J R Soc Interface       Date:  2020-07-08       Impact factor: 4.118

10.  Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.